Journal article
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement
Abstract
Edoxaban is a new oral direct factor Xa inhibitor. The purpose of this study was to evaluate the efficacy and safety of different doses of edoxaban for the prevention of venous thromboembolism (VTE) in patients undergoing elective total hip replacement. A total of 903 patients were randomised to oral edoxaban 15, 30, 60 or 90 mg once daily or subcutaneous dalteparin once daily (initial dose 2,500 IU, subsequent doses 5,000 IU). Both drugs were …
Authors
Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
Journal
Thrombosis and Haemostasis, Vol. 104, No. 03, pp. 642–649
Publisher
Thieme
Publication Date
2010
DOI
10.1160/th10-02-0142
ISSN
0340-6245
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Administration, OralAgedAnticoagulantsArthroplasty, Replacement, HipCanadaDalteparinDouble-Blind MethodDrug Administration ScheduleElective Surgical ProceduresEuropeFactor XaFactor Xa InhibitorsFemaleFibrinolytic AgentsHemorrhageHumansInjections, SubcutaneousLogistic ModelsMaleMiddle AgedPhlebographyPulmonary EmbolismPyridinesRisk AssessmentRisk FactorsThiazolesTime FactorsTreatment OutcomeUnited StatesVenous ThromboembolismVenous Thrombosis